Skip to main content
SpringerLink
Log in

Infections in Critically Ill Solid Organ Transplant Recipients

  • Chapter
Infectious Diseases in Critical Care

  • 2122 Accesses

Abstract

In recent years, advances in surgical techniques, immunosuppressant drugs, diagnostic tests and preventive strategies against a large number of pathogens have achieved considerably lower infection rates among recipients of a solid organ transplant. Certain opportunistic infections such as cytomegalovirus (CMV) and Pneumocystis jiroveci have undergone an important reversal in the past decade. Nevertheless, the appearance of new pathogens and the escalation of antibiotic resistance have altered the spectrum of the microorganisms involved and, consequently, infection management in the transplant patient. Nosocomial infection, in particular hospital-acquired bacterial infection, is presently the main source of infection following transplantation. Up to 53% of infections in a group of heart transplant recipients were considered to be hospital-acquired and 63% of them were bacterial [1]. In liver transplant recipients, 82% of all febrile episodes in a 2-year period were described as nosocomial in origin, with 62% of bacterial etiology [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Waser M, Maggiorini M, Luthy A, Laske A, vorSequesser L, Mohassi P, et al. (1994) Infectious complications in 100 consecutive heart transplant recipients. Eur J Clin Microbiol Infect Dis 13:12–18

    CAS  PubMed  Google Scholar 

  2. Chang FY, Singh N, Gayowski T, Wagener MM, Marino IR (1998) Fever in liver transplant recipients: changing spectrum of etiologic agents. Clin Infect Dis 26:59–65

    CAS  PubMed  Google Scholar 

  3. Carrido RS, Aquado JM, Diaz-Pedrache C, Len O, Montejo M, Moreno A, et al. (2006) A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 82:1457–1462

    Google Scholar 

  4. Linden PK, Miller CB (1999) Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen. Diagn Microbiol Infect Dis 33:113–120

    CAS  PubMed  Google Scholar 

  5. Bauldoff GS, Nunley DR, Manzetti JD, Dauber JH, Keenan RJ (1997) Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 64:748–753

    CAS  PubMed  Google Scholar 

  6. Chang FY, Singh N, Gayowski T, Drenning SD, Wagener MM, Marino IR (1998) Staphylococcus aureus nasal colonization and association with infections in liver transplant recipients. Transplantation 65:1169–1172

    CAS  PubMed  Google Scholar 

  7. Chang FY, Singh N, Gayowski T, Wagener M, Marino IR (1998) Staphylococcus aureus nasal colonization in patients with cirrhosis: prospective assessment of association with infections. Infect Control Hosp Epidemiol 19:328–332

    CAS  PubMed  Google Scholar 

  8. Grems JJ, Hiatt JR, Klein AS, Hart J, El-Khoury G, Winston D, et al. (1998) Disseminated aspergillosis complicating orthotopic liver transplantation for fulminant hepatic failure refractory to corticosteroid therapy. Transplantation 46:479–481

    Google Scholar 

  9. Milstone AP, Brumble LM, Loyd JE, Ely EW, Roberts JR, Pierson RN 3rd, et al. (2000) Active CMV infection before lung transplantation: risk factors and clinical implications. J Heart Lung Transplant 19:744–750

    CAS  PubMed  Google Scholar 

  10. Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C, et al. (2005) Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 41:52–59

    CAS  PubMed  Google Scholar 

  11. Gayowsksi T, Marino IR, Singh N, Doyle H, Wagener MM, Fung JJ, et al. (1998) Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 65:499–504

    Google Scholar 

  12. Singh N (2003) Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 17:113–134

    PubMed  Google Scholar 

  13. Muñoz P, Muñoz V, Fogueda M, Blanes M, Cuervas-Mons V, Moreno A, et al. (2005) Infectious complications after heart transplantation. Results of a prospective national network in Spain (RESITRA). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1567, p 357

    Google Scholar 

  14. Kusne S, Furukawa H, Abu-Elmagd W, Irish W, Rakela J, Fung J et al. (1996) Infectious complications after small bowel transplantation in adults: an update. Transplant Proc 28:2761–2762

    CAS  PubMed  Google Scholar 

  15. Hudnall SD, Rady PL, Tyring SK, Fish JC (1999) Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. Transplantation 67:648–652

    CAS  PubMed  Google Scholar 

  16. Ochiai TA, Nakajima K, Nagata M, Suzuki T, Asano T, Uematsu T, et al. (1987) Effect of a new immunosuppressive agent, FK506 on heterotopic cardiac allotransplantation in the rat. Transplant Proc 19:1284–1286

    CAS  PubMed  Google Scholar 

  17. The U.S. Multicenter FK506 Liver Study Group (1994) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331:1110–1115

    Google Scholar 

  18. Paterson DL, Singh N, Panebianco A, Wannstedt CF, Wagener MM, Gayowski T, et al. (1998) Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 66:593–598

    CAS  PubMed  Google Scholar 

  19. Singh N (1997) Infections in solid organ transplant recipients. In: Wenzel RP (ed) Prevention and control of nosocomial infections. Williams and Wilkins, Baltimore, MD, p 1100

    Google Scholar 

  20. Roenhorst HW, Beelen JM, Middeldorp JM, Schirm J, Tegzess AM, The TH (1985) Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. II. Secondary CMV infections associated with impaired in vitro proliferative responses to mitogens, allogeneic lymphocytes and CMV infected cells. Clin Exp Immunol 61:72–79

    CAS  PubMed  Google Scholar 

  21. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE (1989) Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261:3561–3566

    CAS  PubMed  Google Scholar 

  22. Reinke P, Fietze E, Ode-Hakim S, Prosch S, Lippert J, Ewert R, et al. (1994) Late acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 344:1737–1738

    CAS  PubMed  Google Scholar 

  23. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, et al. (2002) The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 35:974–981

    PubMed  Google Scholar 

  24. de Otero J, Gavalda J, Murio E, Vargas V, Calico I, Llopart L, et al. (1998) Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 26:865–870

    PubMed  Google Scholar 

  25. Singh N, Carrigan DR (1996) Human herpesvirus-6 in transplantation: an emerging pathogen. Ann Intern Med 124:1065–1071

    CAS  PubMed  Google Scholar 

  26. Dockrell DH, Mendez JC, Jones M, Harmsen WS, Ilstrup DM, Smith TF, et al. (1999) Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 67:399–403

    CAS  PubMed  Google Scholar 

  27. Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS, et al. (1997) Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 176:1135–1140

    CAS  PubMed  Google Scholar 

  28. Lee H, Locker J, Nalesnik M, Reyes J, Jaffe R, Alashari M, et al. (1995) The association of Epstein-Barr virus with smooth muscle tumors occurring after organ transplantation. N Engl J Med 332:19–25

    CAS  PubMed  Google Scholar 

  29. Alkan S, Karcher DS, Ortiz A, Khalil S, Akhtar M, Ali MA (1997) Human herpesvirus-8 Kaposi’s sarcoma-associated herpesvirus in organ transplant patients with immunosuppression. Br J Haematol 96:412–414

    CAS  PubMed  Google Scholar 

  30. Boshoff C, Weiss RA (1998) Kaposi’s sarcoma-associated herpesvirus. Adv Cancer Res 75:57–86

    CAS  PubMed  Google Scholar 

  31. Eason JD, Freeman RB, Rohrer RJ, Lewis WD, Jenkins R, Dienstag J, et al. (1994) Should liver transplantation be performed for patients with hepatitis B? Transplantation 57:1588–1593

    CAS  PubMed  Google Scholar 

  32. Singh N, Gayowski T, Wagener MM, Marino IR (1996) Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 61:402–406

    CAS  PubMed  Google Scholar 

  33. Moreno A, Cervera C, Rovira M, Uriburu C, Almela M, De la Camara R, et al. (2005) Bloodstream infection in transplant patients in Spain. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1563, p 356

    Google Scholar 

  34. Wagener MM, Yu VL (1992) Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control 20:239–247

    CAS  PubMed  Google Scholar 

  35. Moreno A, Cervera C, Cofán F, Marco F, Linares L, Alorda C, et al. (2005) Risk factors for the development of bacteremia in renal transplant recipients. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1564, p 356

    Google Scholar 

  36. Cervera C, Moreno A, Puig de la Bellacasa J, Cisteró P, Navasa M, Lumbreras C, et al. (2005) Risk factors for the development of bacteremia in liver transplant recipients. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1565, p 356

    Google Scholar 

  37. George DL, Arnow PM, Fox AS, Baker AL, Thistlethwaite JR, Emond JC, et al. (1991) Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis 13:387–396

    CAS  PubMed  Google Scholar 

  38. Singh N, Chang FY, Gayowski T, Wagener M, Marino IR (1999) Fever in liver transplant recipients in the intensive care unit. Clin Transplant 13:504–511

    CAS  PubMed  Google Scholar 

  39. Len O, Gavaldà J, Puigfel Y, Alvarez M, Alvarez M, Gentil M, et al. (2005) Donor infection and transmission to the recipient of a solid allograft. A prospective study from RESITRA. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1805, p 359

    Google Scholar 

  40. Bonham CA, Dominguez EA, Fukui MB, Paterson DL, Pankey GA, Wagener MM, et al. (1998) Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation 66:1596–1604

    CAS  PubMed  Google Scholar 

  41. Selby R, Ramirez CB, Singh R, Kleopoulos I, Kusne S, Starzl TE, et al. (1997) Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg 132:304–310

    CAS  PubMed  Google Scholar 

  42. Singh N, Yu VL, Gayowski T (1994) Central nervous system lesions in adult liver transplant recipients: clinical review with implications for management. Medicine 73:110–118

    CAS  PubMed  Google Scholar 

  43. Wang FZ, Linde A, Hagglund H, Testa M, Locasciulli A, Ljungman P (1999) Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis 28:562–568

    CAS  PubMed  Google Scholar 

  44. Singh N, Paterson DL (2000) Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 69:2474–2479

    CAS  PubMed  Google Scholar 

  45. Gavalda J, Lama R, Varela A, Vicente JL, Peña F, Gaudo J, et al. (2005) Pneumonia after lung transplantation in the XXI century: a multicenter prospective study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1558, p 354

    Google Scholar 

  46. Cahill BC, Hibbs JR, Savik K, Juni BA, Dosland BM, Edin-Stibbe C, et al. (1997) Aspergillus airway colonization and invasive disease after lung transplantation. Chest 112:1160–1164

    CAS  PubMed  Google Scholar 

  47. Monforte V, Roman A, Gavalda J, Bravo C, Tenorio L, Ferrer A, et al. (2001) Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 20:1274–1281

    CAS  PubMed  Google Scholar 

  48. Monforte V, Gavalda J, Roman A, Lopez R, Bravo C, Pou L, et al. (2004) Pharmacokinetics and efficacy of nebulized ambisome in lung transplantation. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, November 2004; Abstract M-1042, p 419

    Google Scholar 

  49. Singh N, Falestiny M, Rogers P, Reed MJ, Pularski J, Norris R, et al. (1998) Pulmonary infiltrates in the intensive care unit: predictors and outcome. Chest 114:1129–1136

    CAS  PubMed  Google Scholar 

  50. Valera B, Bernardos A, Porras F, Fortun J, Lumbreras C, Len O, et al. (2005) Pneumonia after liver transplantation in the XXI century: a multicenter prospective study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1560, p 355

    Google Scholar 

  51. Jimenez-Jambrina M, Hernandez A, Cordero E, Gurgui M, Alonso L, Blanes M, et al. (2005) Pneumonia after heart transplantation in the XXI century: a multicenter prospective study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1561, p 355

    Google Scholar 

  52. Cisneros JM, Muñoz P, Torres-Cisneros J, Gurgui M, Rodriguez-Hernandez MJ, Aguado JM, et al. (1998) Pneumonia after heart transplantation: a multiinstitutional study. Clin Infect Dis 27:324–331

    CAS  PubMed  Google Scholar 

  53. Valera B, Gentil MA, San-Juan R, Aznar J, Beneyto MI, Marcos MA, et al. (2005) Pneumonia after kidney transplantation in the XXI century: a multicenter prospective study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract k-1559, p 355

    Google Scholar 

  54. Paterson DL, Singh N, Gayowski T, Marino IR (1998) Pulmonary nodules in liver transplant recipients. Medicine 77:50–58

    CAS  PubMed  Google Scholar 

  55. Singh N, Gayowski T, Wagener MM, Marino IR (1999) Pulmonary infiltrates in liver transplant recipients in the intensive care unit. Transplantation 67:1138–1144

    CAS  PubMed  Google Scholar 

  56. Clark BD, Vezza PR, Copeland C, Wilder AM, Abati A (2002) Diagnostic sensitivity of bronchoalveolar lavage versus lung fine needle aspirate. Mod Pathol 15:1259–1265

    PubMed  Google Scholar 

  57. Lapchik MS, Castelo Filho A, Pestana JO, Silva Filho AP, Wey SB (1992) Risk factors for nosocomial urinary tract and postoperative wound infections in renal transplant patients: a matched pair case control study. J Urology 147:994–998

    CAS  Google Scholar 

  58. Everett JE, Wahoff DC, Statz C, Gillingham KJ, Gruessner A, Gruessner RW, et al. (1994) Characterization and impact of wound infection after pancreas transplantation. Arch Surg 129:1310–1316

    CAS  PubMed  Google Scholar 

  59. Asensio A, Ramos A, García-Navarro M, Gavalda J, Quijano Y, Lopez-Medrano F (2005) Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract K-1812, p 360

    Google Scholar 

  60. Gavaldà J, Len O, Rovira M, Borrell N, Cámara R, Cisneros J, et al. (2005) Epidemiology of invasive fungal infections in solid organ and hematopoietic stem cell transplant recipients: a prospective study from RESITRA. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract M-990, p428

    Google Scholar 

  61. Loinaz C, Lumbreras C, Moreno E, Colina F, Fuertes A, Gomez R, et al. (2001) Liver transplantation and hepatitis C virus. Results in a Spanish center since 1989. Hepatogastroenterology 48:1435–1442

    CAS  PubMed  Google Scholar 

  62. Singh N, Gayowski T, Wagener MM, Marino IR (1996) Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 61:402–406

    CAS  PubMed  Google Scholar 

  63. Corell A, Morales JM, Mandrono A, Munoz MA, Andres A, Fuertes A, et al. (1995) Immunosuppression induced by hepatitis C virus infection reduces acute renal transplant rejection. Lancet 346:1497–1498

    CAS  PubMed  Google Scholar 

  64. Stevens DA (2002) Diagnosis of fungal infections: current status. J Antimicrob Chemother 49Suppl 1:11–19

    CAS  PubMed  Google Scholar 

  65. Heussel CP, Kauczor HU, Heussel G, Fischer B, Mildenberger P, Thelen M (1997) Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. AJR Am J Roentgenol 169:1347–1353

    CAS  PubMed  Google Scholar 

  66. Gavalda J, Ruiz I; Grupo de Estudio de Micologia Medica (MICOMED); Grupo de Estudio de Infeccion en el Transplante (GESITRA); Sociedad Española de Enfermedades Infecciosas y Microbiologia Clinica (SEIMC) (2003) Guidelines for the treatment of infection due to Aspergillus spp. Enferm Infecc Microbiol Clin 21:571–578

    PubMed  Google Scholar 

  67. Nosari A, Anghilieri M, Carrafiello G, Guffanti C, Marbello L, Montillo M, et al. (2003) Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica 88:1405–1409

    PubMed  Google Scholar 

  68. Monforte V, Roman A, Gavalda J, López R, Pou L, Simo M, et al. (2003) Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 75:1571–1574

    CAS  PubMed  Google Scholar 

  69. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP (2005) Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41:60–66

    PubMed  Google Scholar 

  70. Munoz P, Rodriguez C, Bouza E, Palomo J, Yanez JF, Dominguez MJ, et al. (2004) Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 4:636–643

    CAS  PubMed  Google Scholar 

  71. Ruiz I, Molina I, Gavalda J, Bueno J, Barrenetxea C, Zuazu J, et al. (2005) Safety and tolerability of nebulized liposomal amphotericin B in hematologic patients. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract M-977, p 425

    Google Scholar 

  72. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, et al. (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for the treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35:359–366

    CAS  PubMed  Google Scholar 

  73. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415

    CAS  PubMed  Google Scholar 

  74. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571

    CAS  PubMed  Google Scholar 

  75. Perea S, González G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF (2002) In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 46:3039–3041

    CAS  PubMed  Google Scholar 

  76. Arikan S, Lozano-Chiu M, Paetznick V, Rex J (2002) In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46:245–247

    CAS  PubMed  Google Scholar 

  77. Jorgensen KJ, Johansen HK, Gotzsche PC (2006) Flaws in design, analysis and interpretation of Pfizer’s antifungal trials of voriconazole and uncritical subsequent quotations. Trials 7:3

    PubMed  Google Scholar 

  78. Caillot D, Mannone L, Cuisenier B, Couaillier JF (2001) Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 7(Suppl 2):54–61

    PubMed  Google Scholar 

  79. Gavalda J, Martin MT, Lopez P, Gomis X, Ramirez JL, Rodriguez D, et al. (2005) Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 49:3028–3030

    CAS  PubMed  Google Scholar 

  80. Kanj SS, Welty-Wolf K, Madden J, Tapson V, Baz MA, Davis RD, et al. (1996) Fungal infections in lung and heart-lung transplant recipients, report of 9 cases and review of the literature. Medicine 75:142–156

    CAS  PubMed  Google Scholar 

  81. Fortun J, Lopez-San Roman A, Velasco JJ, Sanchez-Sousa A, de Vicente E, Nuno J, et al. (1997) Susceptibility of Candida glabrata strains with reduced susceptibility of azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 16:314–318

    CAS  PubMed  Google Scholar 

  82. Gavalda J, Ruiz I (2003) Guidelines for the treatment of invasive fungal infection. Invasive fungal infection by Candida spp. Invasive Fungal Infection Study Group (MICOMED) and Infection in Transplantation Study Group (GESITRA) of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin 21:498–508

    PubMed  Google Scholar 

  83. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Infectious Diseases Society of America (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161–189

    PubMed  Google Scholar 

  84. Olsson M, Sukura A, Lindberg L, Linder E (1996) Detection of Pneumocystis carinii DNA by filtration of air. Scand J Infect Dis 28:279–282

    CAS  PubMed  Google Scholar 

  85. Arend SM, Westendorp RG, Kroon FP, van’tWout JW, Vandenbroucke JP, van Es LA, et al. (1996) Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 22:920–925

    CAS  PubMed  Google Scholar 

  86. Gordon SM, LaRosa SP, Kalmadi S, Arroliga AC, Avery RK, Truesdell-LaRosa L, et al. (1999) Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 28:240–246

    CAS  PubMed  Google Scholar 

  87. Vilchez RA, Fung J, Kusne S (2002) Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2:575–580

    PubMed  Google Scholar 

  88. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell KJ, et al. (2005) Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection. Transplantation 80:1033–1039

    PubMed  Google Scholar 

  89. Singh N, Gayowski T, Singh J, Yu VL (1995) Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis 20:617–620

    CAS  PubMed  Google Scholar 

  90. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP (2006) Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42:e61–65

    PubMed  Google Scholar 

  91. Singh N, Chang FY, Gayowski T, Marino IR (1997) Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clin Infect Dis 24:369–374

    CAS  PubMed  Google Scholar 

  92. Husain S, Alexander BD, Munoz P, Avery RK, Houston S, Pruett T, et al. (2003) Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 37:221–229

    PubMed  Google Scholar 

  93. Singh N, Paterson DL, Chang FY, Gayowski T, Squier C, Wagener MM, et al. (2000) Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis 30:322–327

    CAS  PubMed  Google Scholar 

  94. Shorr AF, Kunkel MJ, Kollef M (2005) Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56:923–929

    CAS  PubMed  Google Scholar 

  95. Bouza E, Cercenado E (2002) Klebsiella and Enterobacter: antibiotic resistance and treatment implications. Semin Respir Infect 17:215–230

    PubMed  Google Scholar 

  96. Paterson DL (2002) Serious infections caused by enteric gram-negative bacilli: mechanisms of antibiotic resistance and implications for therapy of gram-negative sepsis in the transplanted patient. Semin Respir Infect 17:260–264

    PubMed  Google Scholar 

  97. Paterson DL, Singh N, Rihs JD, Squier C, Rihs BL, Muder RR (2001) Control of an outbreak of infection due to extended-spectrum beta-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 33:126–128

    CAS  PubMed  Google Scholar 

  98. Rahal JJ, Urban C, Horn D, et al. (1998) Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 280:1233–1237

    CAS  PubMed  Google Scholar 

  99. Newell KA, Millis JM, Arnow PM, Bruce DS, Woodle ES, Cronin DC, et al. (1998) Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthototic liver transplantation. Transplantation 65:439–442

    CAS  PubMed  Google Scholar 

  100. Papanicolaou GA, Myers BR, Meyers J, Mendelson MH, Lou W, Emre S, et al. (1996) Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 23:760–766

    CAS  PubMed  Google Scholar 

  101. Lundstrom TS, Sobel JD (2004) Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infect Dis Clin North Am 18:651–668

    PubMed  Google Scholar 

  102. Chow JW, Yu VL (1998) Legionella: a major opportunistic pathogen in transplant recipients. Semin Respir Infect 13:132–139

    CAS  PubMed  Google Scholar 

  103. Bangsborg JM, Uldum S, Jensen JS, Bruun BG (1995) Nosocomial legionellosis in three heart-lung transplant patients: case reports and environmental observations. Eur J Clin Microbiol Infect Dis 14:99–104

    CAS  PubMed  Google Scholar 

  104. Patel R, Paya C (1997) Infections in solid-organ recipients. Clin Microbiol Rev 10:86–124

    CAS  PubMed  Google Scholar 

  105. Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:1094–1097

    PubMed  Google Scholar 

  106. Razonable RR, Paya CV, Smith TF (2002) Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic item cell and solid organ transplant recipients. J Clin Microbiol 40:746–752

    PubMed  Google Scholar 

  107. Paya C, Razonable RR (2003) Cytomegalovirus infection after solid transplantation. In: Bowden RA, Ljungman P, Paya CV (eds) Transplant infections, 2nd edn. Lippincott Williams and Wilkins, Philadelphia, p 298

    Google Scholar 

  108. San Juan R, Lumbreras C, Aguado JM, Montejo M, Pumarola T, Rufi G, et al. (2005) Impact of new transplantation practices in the development of cytomegalovirus disease after renal transplantation: a prospective study of the Spanish Network of Infection in Transplantation (RESITRA). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract V-1395, p 487

    Google Scholar 

  109. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD (2002) Cytomegalovirus replication dynamics in CMV-naïve and experienced immunocompromised hosts. J Infect Dis 185:1723–1728

    PubMed  Google Scholar 

  110. Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B (2002) Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 29:903–906

    CAS  PubMed  Google Scholar 

  111. Torre-Cisneros J, Fortun J, Aguado JM, de la Camara R, Cisneros JM, Gavalda J, et al. (2005) Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients. Enferm Infecc Microbiol Clin 23:424–437

    PubMed  Google Scholar 

  112. Paya C, Humar A, Domínguez E, Washburn K, Blumberg E, Alexander B, et al.(2004) Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611–620

    CAS  PubMed  Google Scholar 

  113. Vrtovec B, Thomas CD, Radovancevic R, Frazier OH, Radovancevic B (2004) Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin preemptive treatment in cytomegalovirus-positive heart transplant recipients. J Heart Lung Transplant 23:461–465

    CAS  PubMed  Google Scholar 

  114. Len O, Gavaldà J, Ruiz I, Aguado JM, Borrell N, Cervera C, et al. (2005) Efficacy of valganciclovir in the treatment of cytomegalovirus disease in solid organ transplantation. A prospective study from RESITRA. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 2005; Abstract V-600, p 473

    Google Scholar 

  115. Kusne S, Schwartz M, Breinig MK, Dummer JS, Lee RE, Selby R, et al. (1991) Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 163:1001–1007

    CAS  PubMed  Google Scholar 

  116. Holt ND, Gould FK, Taylor CE, Harwood JF, Freeman R, Healy MD, et al. (1997) Incidence and significance of non-cytomegalovirus viral respiratory infection after adult lung transplantation. J Heart Lung Transplant 16:416–419

    CAS  PubMed  Google Scholar 

  117. Kusne S, Pappo O, Manez R, Pazin G, Carpenter B, Fung JJ, et al. (1995) Varicella zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult transplant recipients. Transplantation 60:619–621

    CAS  PubMed  Google Scholar 

  118. Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV; PV16000 Study Group (2005) Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 192:1331–1339

    PubMed  Google Scholar 

  119. Munoz P, Alvarez P, de Ory F, Pozo F, Rivera M, Bouza E (2002) Incidence and clinical characteristics of Kaposi sarcoma after solid organ transplantation in Spain: importance of seroconversion against HHV-8. Medicine (Baltimore) 81:293–304

    PubMed  Google Scholar 

  120. Preiksaitis JK (2004) New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 39:1016–1023

    PubMed  Google Scholar 

  121. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N, et al. (2005) Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5:2901–2906

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Department, Hospital Vall d’Hebron, P. Vall d’Hebron 119-129, 08035, Barcelona, Spain

    O. Len MD, PhD, J. Gavaldà MD, PhD & A. Pahissa MD, PhD

Authors
  1. O. Len MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Gavaldà MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Pahissa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Critical Care Department, Joan XXIII University Hospital, Carrer Mallafré Guasch, 4, E-43007, Tarragona, Spain

    Jordi Rello MD, PhD  & Alejandro Rodríguez MD, PhD  & 

  2. Medical Intensive Care Unit, Washington University School of Medicine, Barnes-Jewish Hospital, 660 South Euclid Avenue, Campus Box 8052, St. Louis, MO, 63110-1093, USA

    Marin Kollef MD (Professor of Medicine and Director) (Professor of Medicine and Director)

  3. Intensive Care Department, Joan XXIII University Hospital, Carrer Mallafré Guasch, 4, E-43007, Tarragona, Spain

    Emili Díaz MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Len, O., Gavaldà, J., Pahissa, A. (2007). Infections in Critically Ill Solid Organ Transplant Recipients. In: Rello, J., Kollef, M., Díaz, E., Rodríguez, A. (eds) Infectious Diseases in Critical Care. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34406-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34406-3_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34405-6

  • Online ISBN: 978-3-540-34406-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation